Amgen Chooses To Settle In US Soliris IPR Tussle
Victory Could Have Led To 2022 Market Entry
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
